200,000+ products from a single source!
sales@angenechem.com
Home > Fluorides > 131747-41-6
131747-41-6 | 2-(Trifluoromethyl)Isonicotinic Acid
CAS No: 131747-41-6 Catalog No: AG000ZNB MDL No:MFCD07774132
Product Description
Catalog Number:
AG000ZNB
Chemical Name:
2-(Trifluoromethyl)Isonicotinic Acid
CAS Number:
131747-41-6
Molecular Formula:
C7H4F3NO2
Molecular Weight:
191.1074
MDL Number:
MFCD07774132
IUPAC Name:
2-(trifluoromethyl)pyridine-4-carboxylic acid
InChI:
InChI=1S/C7H4F3NO2/c8-7(9,10)5-3-4(6(12)13)1-2-11-5/h1-3H,(H,12,13)
InChI Key:
BZFGKBQHQJVAHS-UHFFFAOYSA-N
SMILES:
OC(=O)c1ccnc(c1)C(F)(F)F
Properties
Complexity:
204
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
191.019g/mol
Formal Charge:
0
Heavy Atom Count:
13
Hydrogen Bond Acceptor Count:
6
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
191.109g/mol
Monoisotopic Mass:
191.019g/mol
Rotatable Bond Count:
1
Topological Polar Surface Area:
50.2A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
1.3
Literature
| Title | Journal |
|---|---|
| Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma. | Cancer letters 20150828 |
| Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. | Cancer chemotherapy and pharmacology 20121201 |
| Eribulin mesylate in patients with refractory cancers: a Phase I study. | Investigational new drugs 20121001 |
| The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120901 |
| Stability of the ready-to-use solutions of eribulin for intravenous infusion. | Annales pharmaceutiques francaises 20120901 |
| Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer. | Expert opinion on drug safety 20120701 |
| Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer. | Clinical therapeutics 20120701 |
| A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. | Investigational new drugs 20120601 |
| A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. | Annals of oncology : official journal of the European Society for Medical Oncology 20120601 |
| Eribulin: a novel cytotoxic chemotherapy agent. | The Annals of pharmacotherapy 20120601 |
| Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. | Annals of oncology : official journal of the European Society for Medical Oncology 20120501 |
| Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study. | Cancer 20120501 |
| Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120501 |
| Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions. | Anticancer research 20120501 |
| Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. | Cancer treatment reviews 20120401 |
| Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a 'physician's choice' control arm in a randomized approval trial. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120315 |
| A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120301 |
| Eribulin -- a review of preclinical and clinical studies. | Critical reviews in oncology/hematology 20120201 |
| Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors. | Drug metabolism and disposition: the biological fate of chemicals 20120201 |
| Eribulin: Heavily pretreated breast cancer: uncertain advantages, excessive adverse effects. | Prescrire international 20120201 |
| Concise and highly stereoselective synthesis of the C20-C26 building block of halichondrins and Eribulin. | Organic letters 20120120 |
| A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer. | Clinical lung cancer 20120101 |
| Eribulin mesylate for the treatment of late-stage breast cancer. | Expert opinion on pharmacotherapy 20111201 |
| Eribulin mesylate. | Clinical cancer research : an official journal of the American Association for Cancer Research 20111101 |
| Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next? | Advances in therapy 20111101 |
| [Anti-tumor mechanism and clinical efficacy of Eribulin (Halaven®), a new microtubulin inhibitor approved for treatment of metastatic breast cancer]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20111101 |
| Eribulin in soft-tissue sarcomas. | The Lancet. Oncology 20111001 |
| Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. | The Lancet. Oncology 20111001 |
| Natural product drug discovery: the successful optimization of ISP-1 and halichondrin B. | Current opinion in chemical biology 20110801 |
| Eribulin. | Drugs 20110709 |
| Interactions of halichondrin B and eribulin with tubulin. | Journal of chemical information and modeling 20110627 |
| Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. | Cancer research 20110601 |
| Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110501 |
| [Eribulin: a new therapeutic option in intensely pretreated metastatic cancer of the breast?]. | Bulletin du cancer 20110501 |
| Eribulin mesylate (Halaven) for breast cancer. | The Medical letter on drugs and therapeutics 20110418 |
| Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. | Investigational new drugs 20110401 |
| Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells. | Xenobiotica; the fate of foreign compounds in biological systems 20110401 |
| Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility. | Bioorganic & medicinal chemistry letters 20110315 |
| Novel second generation analogs of eribulin. Part III: Blood-brain barrier permeability and in vivo activity in a brain tumor model. | Bioorganic & medicinal chemistry letters 20110315 |
| Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo. | Bioorganic & medicinal chemistry letters 20110315 |
| Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. | Lancet (London, England) 20110312 |
| EMBRACE, eribulin, and new realities of advanced breast cancer. | Lancet (London, England) 20110312 |
| Eribulin mesylate. | Nature reviews. Drug discovery 20110301 |
| Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer. | Future oncology (London, England) 20110301 |
| Nontaxane microtubule dynamics inhibitors. | Clinical advances in hematology & oncology : H&O 20110301 |
| The place for eribulin in the treatment of metastatic breast cancer. | Current oncology reports 20110201 |
| Editorial: Marine Natural Products themed issue. | Natural product reports 20110201 |
| Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. | Cancer research 20110115 |
| Eribulin approved for advanced breast cancer. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110101 |
| New drugs: Ceftaroline fosamil, pegloticase, and eribulin mesylate. | Journal of the American Pharmacists Association : JAPhA 20110101 |
| Complex synthesis yields breast-cancer therapy. | Nature 20101202 |
| Advances in therapy: eribulin improves survival for metastatic breast cancer. | Anti-cancer drugs 20101101 |
| Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100901 |
| Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer. | Drugs of today (Barcelona, Spain : 1998) 20100901 |
| Eribulin mesylate for the treatment of breast cancer. | Expert opinion on pharmacotherapy 20100601 |
| Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. | Clinical breast cancer 20100401 |
| Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. | Biochemistry 20100216 |
| [New drugs in metastatic castration-resistant prostate cancer]. | Bulletin du cancer 20100101 |
| Second generation synthesis of C27-C35 building block of E7389, a synthetic halichondrin analogue. | Organic letters 20091015 |
| Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation. | Biochemistry 20090825 |
| The halichondrins and E7389. | Chemical reviews 20090701 |
| Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090620 |
| Eribulin: rediscovering tubulin as an anticancer target. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090615 |
| Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090615 |
| A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090615 |
| Novel anti-tubulin cytotoxic agents for breast cancer. | Expert review of anticancer therapy 20090201 |
| A high-performance liquid chromatography-tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20081115 |
| Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. | Cancer chemotherapy and pharmacology 20080901 |
| Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. | Molecular cancer therapeutics 20080701 |
| Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. | Seminars in oncology 20080401 |
| Promising novel cytotoxic agents and combinations in metastatic prostate cancer. | Cancer journal (Sudbury, Mass.) 20080101 |
| Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer. | Current opinion in investigational drugs (London, England : 2000) 20071201 |
| Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. | Molecular pharmacology 20061201 |
| Scientists are searching the seas for cancer drugs. | Journal of the National Cancer Institute 20060517 |
| Chemistry. The renaissance of natural products as drug candidates. | Science (New York, N.Y.) 20051021 |
| The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. | Molecular cancer therapeutics 20050701 |
| Macrocyclic ketone analogues of halichondrin B. | Bioorganic & medicinal chemistry letters 20041115 |
| In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. | Cancer research 20010201 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.